Ipsen, Genfit's Elafibranor Shows Promise In Primary Biliary Cholangitis Patients
Portfolio Pulse from Vandana Singh
Ipsen SA and Genfit SA announced positive topline data from the Phase 3 ELATIVE trial evaluating the efficacy and safety of elafibranor for primary biliary cholangitis (PBC). The trial met its primary composite endpoint, with 51% of patients on elafibranor 80mg exhibiting a cholestasis response compared to 4% on placebo. Ipsen plans to discuss these results with regulatory bodies and aims to move forward with regulatory submissions to the FDA and the European Medicines Agency. Genfit shares are down 14.30% at $3.47 on the last check Friday.
June 30, 2023 | 6:03 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Genfit's shares are down 14.30% despite positive trial results for elafibranor.
Despite the positive trial results, the market reacted negatively to the news, causing Genfit's shares to drop. This could be due to a variety of factors, including market volatility or investor sentiment.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100
POSITIVE IMPACT
Ipsen plans to discuss the positive trial results with regulatory bodies and aims to move forward with regulatory submissions.
The positive trial results are a good sign for Ipsen, and the company's plans to discuss these results with regulatory bodies could potentially lead to regulatory approval for elafibranor, which would be a positive development for the company.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100